Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Fisher GA Jr, et al. Among authors: liyanage n. Oncologist. 2018 Jan;23(1):16-24. doi: 10.1634/theoncologist.2017-0284. Epub 2017 Oct 16. Oncologist. 2018. PMID: 29038234 Free PMC article. Clinical Trial.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Pavel ME, et al. Among authors: liyanage n. Oncologist. 2019 Apr;24(4):463-474. doi: 10.1634/theoncologist.2018-0217. Epub 2018 Oct 24. Oncologist. 2019. PMID: 30355775 Free PMC article. Clinical Trial.
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI; ELECT Study Investigators. Fisher GA Jr, et al. Among authors: liyanage n. Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR. Endocr Pract. 2018. PMID: 29547049 Clinical Trial.
Novel Measurement of the Neutron Magnetic Form Factor from A=3 Mirror Nuclei.
Santiesteban SN, Li S, Abrams D, Alsalmi S, Androic D, Aniol K, Arrington J, Averett T, Ayerbe Gayoso C, Bane J, Barcus S, Barrow J, Beck A, Bellini V, Bhatt H, Bhetuwal D, Biswas D, Camsonne A, Castellanos J, Chen J, Chen JP, Chrisman D, Christy ME, Clarke C, Covrig S, Cruz-Torres R, Day D, Dutta D, Fuchey E, Gal C, Garibaldi F, Gautam TN, Gogami T, Gomez J, Guèye P, Hague TJ, Hansen JO, Hauenstein F, Henry W, Higinbotham DW, Holt RJ, Hyde C, Itabashi K, Kaneta M, Karki A, Katramatou AT, Keppel CE, King PM, Kurbany L, Kutz T, Lashley-Colthirst N, Li WB, Liu H, Liyanage N, Long E, Lovato A, Mammei J, Markowitz P, McClellan RE, Meddi F, Meekins D, Michaels R, Mihovilovič M, Moyer A, Nagao S, Nguyen D, Nycz M, Olson M, Ou L, Owen V, Palatchi C, Pandey B, Papadopoulou A, Park S, Petkovic T, Premathilake S, Punjabi V, Ransome RD, Reimer PE, Reinhold J, Riordan S, Rocco N, Rodriguez VM, Schmidt A, Schmookler B, Segarra EP, Shahinyan A, Širca S, Slifer K, Solvignon P, Su T, Suleiman R, Tang L, Tian Y, Tireman W, Tortorici F, Toyama Y, Uehara K, Urciuoli GM, Votaw D, Williamson J, Wojtsekhowski B, Wood S, Ye ZH, Zhang J, Zheng X; Jefferson Lab Hall A Collaboration. Santiesteban SN, et al. Among authors: liyanage n. Phys Rev Lett. 2024 Apr 19;132(16):162501. doi: 10.1103/PhysRevLett.132.162501. Phys Rev Lett. 2024. PMID: 38701469
134 results